Preparation and Characterization of an Oridonin Nanosuspension for Solubility and Dissolution Velocity Enhancement

REFERENCES

• Chen S., Gao J., Halicka H. D., Huang X., Traganos F., Darzynkiewicz Z. The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int. J. Oncol. 2005; 26: 579–588
   PubMedGoogle Scholar
• Choi J. Y., Yoo J. Y., Kwak H. S., Nam B. U., Lee J. Role of polymeric stabilizers for drug nanocrystal dispersions. Current Applied Physics 2005; 5: 472–474
   Web of Science ®Google Scholar
• Clement M. A., Pugh W., Parikh I. Tissue distribution and plasma clearance of a novel microcrystal-encapsulated flurbiprofen formulation. Pharmacologist 1992; 34: 204–211
   Google Scholar
• Fujita T., Takeda Y., Sun H. D., Minami Y., Marunaka T., Takeda S. Cytotoxic and antitumor activities of Rabdosia diterpenoids. Planta. Med. 1988; 54: 414–417
   PubMedGoogle Scholar
• Hecq J., Deleers M., Fanara D., Vranckx H., Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 2005; 299: 167–177
   PubMed Web of Science ®Google Scholar
• Ikezoe T., Chen S. S., Tong X. J., Heber D., Taguchi H., Koeffler H. P. Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int. J. Oncol. 2003; 23: 1187–1193
   PubMed Web of Science ®Google Scholar
• Jacobs C., Kayser O., Muller R. H. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Inter. J. Pharm. 2000; 196: 161–164
   PubMed Web of Science ®Google Scholar
• Keck C. M., Muller R. H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 2006; 6: 3–16
   Google Scholar
• Kipp J. E. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 2004; 284: 109–122
   PubMed Web of Science ®Google Scholar
• Kocbek P., Baumgartner S., Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Inter. J. Pharm. 2006; 312: 179–186
   PubMed Web of Science ®Google Scholar
• Krause K. P., Muller R. H. Production and characterisation of highly concentrated nanosuspensions by high pressure homogenisation. Int. J. Pharm. 2001; 214: 21–24
   PubMed Web of Science ®Google Scholar
• Lee J., Lee S. J., Choi J. Y., Yoo J. Y., Ahn C. H. Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion. Eur. J. Pharm. Sci. 2005; 24: 441–449
   PubMed Web of Science ®Google Scholar
• Liversidge E. M., Liversidge G. G., Cooper E. R. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003; 18: 113–120
   PubMed Web of Science ®Google Scholar
• Liversidge G. G., Cundy K. C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 1995; 125: 91–97
   Web of Science ®Google Scholar
• Ch Li, Y., Dong L., Jia A., Chang X. M., Xue H. Preparation and characterization of solid lipid nanoparticles loaded traditional Chinese medicine. Inter. J. Bio. Macro. 2006; 38: 296–299
   PubMed Web of Science ®Google Scholar
• Liu Ch. J., Zhao Zh. H. Research progress of oridonin. Chin. Pharm. J. 1998; 33: 577–581
   Google Scholar
• Moschwitzera J., Achleitnerb G., Pomperb H., Muller R. H. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur. J. Pharm. Biopharm. 2004; 58: 615–619
   PubMed Web of Science ®Google Scholar
• Muller R. H., Becker R., Kruss B., Peters K. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. U.S. Patent No. 5,858,410, 1999
   Google Scholar
• Muller R. H., Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int. J. Pharm. 2002; 237: 151–161
   PubMed Web of Science ®Google Scholar
• Muller R. H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the Future. Adv. Drug. Deliv. Rev. 2001; 47: 3–19
   PubMed Web of Science ®Google Scholar
• Osawa K., Yasuda H., Maruyama T., Morita H., Takeya K., Itokawa H. Antibacterial trichorabdal diterpenes from Rabdosia trichocarpa. Phytochemistry 1994; 36: 1287–1291
   PubMed Web of Science ®Google Scholar
• Patravale V. B., Date A. A., Kulkarni R. M. Nanosuspensions: A promising drug delivery strategy. J. Pharm. Pharmaco. 2004; 56: 827–840
   Web of Science ®Google Scholar
• Peters K., Leitzke S., Diederichs J. E., Borner K., Hahn H., Muller R. H., et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Antimicrob. Chemother. 2000; 45: 77–83
   PubMed Web of Science ®Google Scholar
• Siostrom B., Kronberg B., Carlfors J. A method for the preparation of submicron particles of sparingly water-soluble drugs by precipitation in oil-in-water emulsions: 1. Influence of emulsification and surfactant concentration. J. Pharm. Sic. 1993; 82: 579–583
   PubMed Web of Science ®Google Scholar
• White R. D., Wong J., Kipp J., Barber T., Glosson J., Kerzee J., et al. Pre-clinical evaluation of itraconazole nanosuspension for intravenous injection. Toxicol. Sci. 2003; 72: 51–59
   Web of Science ®Google Scholar
• Xing J., Zhang D. R., Tan T. W. Studies on the oridonin-loaded poly(d, l-lactic acid) nanoparticles in vitro and in vivo. Int. J. Bio. Macro. 2007; 40: 153–158
   PubMed Web of Science ®Google Scholar
• Zhang D. R., Ren T. C. Pharmaceutical progress of oridonin. Chin. Pharm. J. 2003; 38: 817–820
   Google Scholar
• Zhang D. R., Tan T. W., Gao L. Preparation of oridonin-loaded SLN and studies on it in vitro and in vivo. Nanotech 2007; 17: 5821–5828
   Web of Science ®Google Scholar
• Zhang J. X., Han Q. B., Zhao A. H., Sun H. D. Diterpenoids from Isodon japonica. Fitoterapia 2003; 74: 435–438
   PubMed Web of Science ®Google Scholar
• Zhang Y., Wang J., Lou L. G., Zhang T. M., Hou J. W., Xin W. J. Scavenging effect of oridonin on active oxygen free radicals. Henan. Med. Res. 1999; 8: 100–104
   Google Scholar
• Zhang Y. B., Kou X., Lu J. Sh., Wang G. H. Research on the oridonin-β-cyclodextrin complex. Chinese Traditional and Herbal Drugs 2001; 24: 131–132
   Google Scholar